• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Small Innovators & Niche CROs

    Focus on Science

    Rapid and Data Rich Chromatographic Method Development

    Preparing Your Post Pandemic Talent Strategy

    How Modern Near-Infrared Came to Be
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Frontage Expands Capabilities at its Clinical Site in Secaucus, NJ

    Ascendia Pharmaceuticals Poised for Expansion

    Bora Pharmaceuticals Adds Roller Compaction Capabilities

    Merck KGaA Selects PRA’s Remote Patient Monitoring Platform

    AGC Biologics Appoints Jun Takami GM of Chiba Site
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Ascendia Pharmaceuticals Poised for Expansion

    Bora Pharmaceuticals Adds Roller Compaction Capabilities

    Alkermes, Merck Enter Clinical Trial and Supply Agreement

    Sterling Pharma Solutions Acquires ADC Biotechnology

    Moderna, Catalent Enter Long-Term Strategic Vax Pact
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Cryoport Acquires Critical Transport Solutions Australia

    PharmParts – This Makes Sense!

    Securing Your API Supply Chain: Three Keys to Success

    Enteris BioPharma: Custom Solutions – From Bench to Market

    The Benefits of Outsourcing Cold Storage
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Frontage Expands Capabilities at its Clinical Site in Secaucus, NJ

    Ascendia Pharmaceuticals Poised for Expansion

    Merck KGaA Selects PRA’s Remote Patient Monitoring Platform

    Agilex Biolabs Acquires TetraQ for APAC Expansion Plans

    Alkermes, Merck Enter Clinical Trial and Supply Agreement
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    What Will Change at FDA for 2021?

    RBQM Comes of Age: COVID as a Catalyst for Change

    Post-Pandemic Regulations

    Enteris BioPharma: Custom Solutions – From Bench to Market

    Metrics Contract Services Completes Russian Regulatory Inspection
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Syngene

    Baxter BioPharma Solutions

    PCI Pharma Services

    Adare Pharma Solutions

    Almac Group
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Aphena Pharma Solutions

    Adare Pharma Solutions

    Almac Group

    Emergent BioSolutions

    Baxter BioPharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    India Report

    The Orphan Promise

    New policy on rare disease treatments likely soon

    The Orphan Promise
    Related CONTENT
    • Mogene
    • Risk-Based Monitoring
    • Getting PAT into Bioprocessing CMOs
    • Lilly's CYRAMZA Gains Fifth Indication
    • My Head is in The Cloud(s)
    S. Harachand, Contributing Editor06.13.19
    It was not long ago that Alembic Pharma informed the Bombay Stock Exchange that its associate company, Rhizen Pharmaceuticals S.A. secured the orphan drug designation for tenalisib from the U.S. FDA. Tenalisib is a selective and orally active dual PI3K delta/gamma inhibitor, for the treatment of peripheral T-cell lymphoma.

    The announcement sounded special to the investors of the mid-cap firm from Vadodara, in the western Indian state of Gujarat, because the news came at a time when the industry is riding a wave of orphan drugs. Drugs for uncommon conditions that usually affect a small number of patients have been historically neglected by drug majors. The so-called ‘orphan drugs,’ however, sprung to popularity in recent years whan the top regulators started incentivizing their development.

    The FDA provides 7-year marketing exclusivity, tax credits for clinical development costs, exemption of filing fees and assistance during the development process. Whereas orphan drugs get 10 years of exclusivity in Europe, plus extra time for pediatric indications. In addition to a quick path to regulatory approval, orphan drugs have an opportunity to generate convincing clinical safety and efficacy data with very limited patient populations, compared to those drugs addressing diseases which are much more common, experts point out. 

    Smaller trials can mean significant development cost savings, as well. Recent analyses of firms with orphan products came out with the finding that they are more profitable than those without. Of late, applications seeking marketing authorizations for orphan drugs have risen to unprecedented levels. The FDA granted approval for 174 drugs with orphan indications during the two year period starting from 2017. The number is probably the highest granted by the agency since the enactment of the Orphan Drug Act in 1983.

    Inevitably, the orphan drug market is set for steady and inexorable growth. According to a report by Evaluate Pharma, sales of orphan drugs are expected to reach $224 billion by 2024 growing at a 12% CAGR through the year. “Growth rates approximately double those of the overall prescription drugs market and the mean cost per patient per year of the top 100 orphan products in the U.S. hitting $150,854 in 2018 versus $33,654 for a non-orphan drug, explain much of the allure,” the report says.

    The acquisition of orphan drug firms will dominate the M&A strategies of bigger firms. The pharma analysis group points to Roche’s acquisition of Spark Therapeutics for $4.8 billion in February as exemplifying the trend. Spark’s Luxturna, the first approved gene therapy for inherited retinal disease, has a current list price of $425,000 per eye.

    Novartis reached a $8.7 bilion deal to buy AveXis and its spinal muscular atrophy candidate, Zolgensma in April last year. Pfizer announced an agreement to acquire all the shares of Therachon Holding AG, in May. Therachon’s investigational TA-46, a human fibroblast growth factor receptor 3 for the treatment of achondroplasia, has received Orphan Drug Designation from both the EMA and FDA.

    India, reportedly, has a higher rare diseases population than the world average. It is estimated that the country has over 70 million patients with any of 7,000 plus diseases classified under rare or uncommon conditions. The health ministry is in the process of framing new rules. The ‘National Policy for the Treatment of Rare Diseases 2017,’ which was in force, has been kept in abeyance until the new policy is issued, the government said.

    With a rare disease population which is more than that of the U.S. and EU combined, India represents a lucrative market to developers and pharma firms looking to expand their orphan operations, according to the Organization for Rare Diseases India (ORDI), a national non-profit organization representing the patients and other stakeholders of rare diseases in India.
    The need for orphan treatments is huge, and the awareness about the diseases is increasing. Drug firms in India are receiving no formal incentives from the government and hence patients with rare diseases have to rely on imported drugs. These treatments are often unaffordable. So, besides enacting an orphan drugs legislation with provisions for incentives for orphan drug developers, the government needs to create a framework that is conducive for the manufacturing of orphan drugs in India, according to ORDI.

    As part of the initiative to have a comprehensive strategy to deal with the rare diseases burden, the government has exempted drugs that are used for treatment of a disease that qualifies as an orphan disease from price control, through an order in January. The orphan drug exemption is expected to encourage domestic companies to develop drugs for orphan diseases and to foreign pharmaceutical companies to market their drugs in India. However, the health ministry is yet to come out with the criteria that will apply to determine an orphan disease. Experts aver that this may lag things further due to the absence of disease prevalence data.


    S. Harachand
    Contributing Editor

    S. Harachand is a pharmaceutical journalist based in Mumbai. He can be reached at harachand@gmail.com.
    Related Searches
    • orphan
    • prescription
    • patients
    • roche
    Suggested For You
    Mogene Mogene
    Risk-Based Monitoring Risk-Based Monitoring
    Getting PAT into Bioprocessing CMOs Getting PAT into Bioprocessing CMOs
    Lilly Lilly's CYRAMZA Gains Fifth Indication
    My Head is in The Cloud(s) My Head is in The Cloud(s)
    Swissfillon Completes Successful FDA Inspection Swissfillon Completes Successful FDA Inspection
    Financial Report: Pfizer Financial Report: Pfizer
    Aduro Biotech Appoints CMO Aduro Biotech Appoints CMO
    The Unfolding Pharma Product Mix The Unfolding Pharma Product Mix
    KASA to Support Generic Drug Review KASA to Support Generic Drug Review
    The Embedded CDMO The Embedded CDMO
    The Premier Source for Pharmaceutical Process and Packaging Equipment The Premier Source for Pharmaceutical Process and Packaging Equipment
    Solid Dose Manufacturing: It’s Time to Trade-in Your 1952 Studebaker Solid Dose Manufacturing: It’s Time to Trade-in Your 1952 Studebaker
    Are We Embracing FDA’s Messages? Are We Embracing FDA’s Messages?
    Gliknik Receives $15M Milestone from Pfizer Gliknik Receives $15M Milestone from Pfizer

    Related India Report

    • Injectables Firms Expand Capacity

      Injectables Firms Expand Capacity

      CDMOs see steriles demand grow.
      S. Harachand, Contributing Editor 11.17.20

    • Supply Chain Woes Vex Markets

      Supply Chain Woes Vex Markets

      Indian players ramp up chloroquine production
      S. Harachand, Contributing Editor 09.09.20

    • HCQ Comes Center Stage

      HCQ Comes Center Stage

      Indian players ramp up chloroquine production
      S. Harachand, Contributing Editor 05.05.20


    • Supply Chain
      Oral Solids Makers Face Corona Heat

      Oral Solids Makers Face Corona Heat

      CDMOs fear supply disruptions, price increases.
      S. Harachand, Contributing Editor 03.04.20

    • Biosimilars
      The Similar Mantra

      The Similar Mantra

      Early birds bet big on biosimilars.
      S. Harachand, Contributing Editor 01.28.20

    • APIs
      India to Track API Packs

      India to Track API Packs

      India is mulling a shakeup in the regulations governing the distribution of pharmaceutical products.
      S. Harachand, Contributing Editor 11.20.19


    • R&D
      Indian Firms Ramp Up R&D

      Indian Firms Ramp Up R&D

      Accelerating on research spend.
      S. Harachand, Contributing Editor 10.15.19

    • Cytotoxics and High Potency Manufacturing
      Highly Potent Expansions

      Highly Potent Expansions

      CDMOs see HPAPI demand rising
      S. Harachand, Contributing Editor 09.16.19

    • Biologics, Proteins, Vaccines
      Ebullient Bio CMOs

      Ebullient Bio CMOs

      Firms see rich dividends from biosimilars
      S. Harachand, Contributing Editor 05.07.19


    • R&D
      Strategic Discovery

      Strategic Discovery

      CROs top offerings with biology skills.
      S. Harachand , Contributing Editor 10.10.18

    • HPAPI Outsourcing Likely to Gain Traction

      HPAPI Outsourcing Likely to Gain Traction

      A number of highly potent drugs will soon fall into the generic domain
      S. Harachand, Contributing Editor 09.11.18

    • Packaging Majors Expand Base in India

      Packaging Majors Expand Base in India

      India’s pharma packaging market is growing at a faster pace than other world markets
      S. Harachand, Contributing Editor 03.09.18


    • Acquisition Spree

      Acquisition Spree

      Indian firms topped the list of aggressive bidders even as the frenzy of deal making in the global generics space passes into
      S. Harachand, Contributing Editor 01.30.18

    • Drug Delivery
      Growing NDDS Portfolios

      Growing NDDS Portfolios

      Generic drugs on novel delivery platforms
      S. Harachand, Contributing Editor 10.11.17

    • Supply Chain
      Marketing Code Round The Corner

      Marketing Code Round The Corner

      Proposal to limit giveaways; offenders face product ban
      S. Harachand, Contributing Editor 09.01.17

    Trending
    • Sterling Pharma Solutions Acquires ADC Biotechnology
    • Ascendia Pharmaceuticals Poised For Expansion
    • Sanofi To Build New $700M Flu Vaccine Facility In Canada
    • Frontage Expands Capabilities At Its Clinical Site In Secaucus, NJ
    • Merck KGaA Selects PRA’s Remote Patient Monitoring Platform
    Breaking News
    • Bora Pharmaceuticals Adds Roller Compaction Capabilities
    • Ascendia Pharmaceuticals Poised for Expansion
    • Frontage Expands Capabilities at its Clinical Site in Secaucus, NJ
    • Merck KGaA Selects PRA’s Remote Patient Monitoring Platform
    • AGC Biologics Appoints Jun Takami GM of Chiba Site
    View Breaking News >
    CURRENT ISSUE

    April 2021

    • Small Innovators & Niche CROs
    • Focus on Science
    • Rapid and Data Rich Chromatographic Method Development
    • Preparing Your Post Pandemic Talent Strategy
    • How Modern Near-Infrared Came to Be
    • Securing Your API Supply Chain: Three Keys to Success
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Kyowa Hakko Launches Heat-Treated Probiotic Strain for Eye Health
    CGA-7 Green Coffee Extract by Vidya Herbs Achieves Self-Affirmed GRAS Status
    Nutritional Complex Evidenced to Reduce Preterm Birth
    Coatings World

    Latest Breaking News From Coatings World

    Chromaflo Technologies to Sponsor and Exhibit at the North American Pultrusion Conference 2021
    Barentz Expands Canadian CASE Team
    Shepherd Color Company Opens Sales Office in China
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    CMS Establishes New Payment for Pelvalon’s Eclipse System
    Varian, Google Cloud Partner to Bring Convenience to Cancer Therapy
    Resonetics Leases New Manufacturing Space in Costa Rica
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Frontage Expands Capabilities at its Clinical Site in Secaucus, NJ
    Ascendia Pharmaceuticals Poised for Expansion
    Bora Pharmaceuticals Adds Roller Compaction Capabilities
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Revlon Unveils New Fragrances Featuring Megan Thee Stallion & Sofia Carson
    Henkel Management Board Welcomes Wolfgang König
    Mielle Organics Gets a Major Investment
    Happi

    Latest Breaking News From Happi

    Nature’s Beauty Debuts Vegan Natural Body Care at Walgreens
    Estée Lauder Expands Beautiful Fragrance Collection
    The Honest Company Files for IPO
    Ink World

    Latest Breaking News From Ink World

    SE-DA Invests in Kornit Presto S
    Kumon North America Adds Speedmaster XL 106 from Heidelberg
    Iron Oxide Pigments Market to Register 4.7% CAGR from 2021 to 2028: GVR
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Dantex elevates Joseph Sanchez to digital business development manager
    Mactac's Kevin Clunie joins TLMI panel
    MacDermid announces two new global sales roles
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Precision Textiles Offers Biodegradable Medical Fabric
    Northshore Launches Megamax Briefs in New Colors
    Essity Acquires Distribution Rights to Sorbact in Australia and New Zealand
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    New Biosealant Could Stabilize Cartilage, Boost Healing After Injury
    Google Executive Joins SeaSpine's Board of Directors
    HSS and LimaCorporate Open Provider-Based 3D Design and Printing Facility
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Tive Multi-sensor Tracker Solo 5G Relies on Sensirion SHT33
    VTT in 2020: Successful Year Despite Globally Challenging Times
    Lux Research: 3D Printing Market to Reach $51 Billion in 2030

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login